MedTrace Logo

Safety Study of Adjuvant Docetaxel-Carboplatin Treatment for Resected Lung Cancer

NCT00883675 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 133

Last updated 2013-12-18

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether it is safe to treat lung cancer patients who have undergone an attempt at curative resection with the combination of docetaxel and carboplatin.

Conditions

Interventions

DRUG

Docetaxel-Carboplatin

Docetaxel: 75 mg/m2 over 1 hour every 3 weeks for 3 doses Carboplatin AUC 5.5 over 0.5 to 1 hour every 3 weeks for 3 doses

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • Michael Mann

    lead NETWORK

Principal Investigators

  • David Jablons, MD · Maestro Clinical

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2012-09-30
Completion
2012-12-31

Countries

  • United States
  • China

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00883675 on ClinicalTrials.gov